Back to search

FRIMEDBIO-Fri prosj.st. med.,helse,biol

Neoadjuvant Avastin in Breast Cancer (Neo-Ava) - an integrated molecular approach to treatment biology.

Awarded: NOK 4.4 mill.

-

Despite the improved results obtained by more aggressive and individual response tailored therapy, patients with large tumor still have a less favourable outcome compared to patients diagnosed with smaller tumors. Whether antiangiogenic treatment strategi es as bevacizumab may improve the tumor response and eventually the prognosis for these patients, is not known. The role of such treatment in combination with endocrine therapy has not been evaluated in these patients, but is of interest to explore. Large studies are ongoing, enrolling patients for treatment with chemotherapy in combination with bevacizumab. This project integrates in a randomized fashion neoadjuvant treatment with bevacizumab in locally advanced breast cancer and a detailed analysis of t he breast cancer disease. Knowledge of how such treatment combinations influences the gene expression profiles, metabolomics and the signaling pathways in the tumor cells may be of significant impact for the interpretation of the treatment results in pati ents. In the event of treatment resistance and failures, such analyses can give clues to the possible responsible mechanisms for this outcome, and be used as guidelines for further development of viable therapeutic strategies. In addition, angiogenic gen e expression profiles and signaling pathway signatures in responding tumors may assist in the selection of patients for such treatment.

Funding scheme:

FRIMEDBIO-Fri prosj.st. med.,helse,biol

Funding Sources